Iodized oil marking guided biopsy of hepatic space-occupying lesions under the protection of hepatic artery catheterization Authors: Zhengyu Zhang, Yanxi Xiong, Jianxia Xu, Xiaoshan Huang, Xingwu Xie Published: 2025 ABSTRACT ObjectiveTo investigate the efficacy and safety of iodized oil marking-guided percutaneous biopsy for hepatic space-occupying lesions under hepatic arterial catheter protection.MethodsA retrospective analysis was performed on 39 patients who underwent iodized oil marking-guided percutaneous biopsy of hepatic space-occupying lesions with hepatic arterial catheter protection. Pathological diagnostic results and postoperative complications were evaluated.ResultsAll 39 lesions were successfully marked with iodized oil, and tissue samples were obtained without technical failure. Of these, 35 cases were pathologically positive, yielding a positivity rate of 89.7% and a true-positive rate of 100%. Four cases were pathologically negative, among which one was later confirmed as a false negative, resulting in a false-negative rate of 25% and an overall diagnostic accuracy of 97.4%. Minor postoperative complications occurred in 13 patients, including abdominal pain in 10 cases (25.6%) and subcapsular microbleeding in 3 cases (7.7%), all of which resolved with symptomatic treatment without the need for special intervention. One case (2.6%) of hepatic arterial bleeding was successfully managed with emergency transcatheter arterial embolization, with no serious adverse events reported.ConclusionsIodized oil marking-guided percutaneous biopsy with hepatic arterial catheterization for hemorrhage control is effective and safe for hepatic space-occupying lesions. It enhances lesion localization, reduces operator dependence, and enables immediate hemostasis, making it suitable for high-risk or difficult-to-localize lesions. Background Hepatic space-occupying lesions (HSOLs) encompass diverse pathological types with distinct treatment strategies and prognoses, making definitive pathological diagnosis critical for individualized therapy. According to the Clinical Practice Guidelines for Hepatobiliary Cancers issued by the National Comprehensive Cancer Network (NCCN) [1], histological diagnosis is particularly important for hepatic lesions lacking typical imaging characteristics, and percutaneous biopsy plays a key role in the diagnosis of such lesions. Ultrasound (US)-guided biopsy is the most common approach, offering real-time imaging; however, its utility is limited for subdiaphragmatic, deep-seated, or small lesions (< 30 mm) due to intestinal gas interference, rib shadowing, and reduced visualization [2]. Contrast-enhanced US improves diagnostic yield but provides no protection against bleeding [3]. Computed tomography (CT)-guided biopsy is a supplementary option, yet non-contrast CT may fail to delineate isoattenuating lesions, and contrast-enhanced CT is constrained by rapid contrast clearance [4]. Magnetic resonance imaging (MRI)-guided biopsy is rarely used due to instrument incompatibility and motion artifacts [5]. Notably, conventional guidance techniques only localize lesions without therapeutic benefits or bleeding risk mitigation. Iodized oil, widely used in transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC), exhibits selective deposition in tumor vasculature [6], making it a potential marker for biopsy targeting. Combined with hepatic arterial catheterization, it may enable immediate hemostasis if bleeding occurs. This study evaluated the clinical value of iodized oil marking-guided percutaneous biopsy with hepatic arterial catheterization for HSOLs. Materials and methods Patients This study adhered to the Declaration of Helsinki (1975) and was approved by the Ethics Committee of Shiyan People’s Hospital of Hubei Medical University (Exemption No.: 2020-012). All patients provided written informed consent prior to treatment. We retrospectively examined the clinical data and imaging information of patients who underwent Iodized oil marking-guided biopsy of liver occupying lesions under the protection of hepatic artery catheterization at the People’s Hospital Affiliated to Hubei University of Medicine from January 2020 to February 2025. A total of 39 records that met the following research requirements were obtained (Fig. 1).Inclusion criteria: a. HSOLs identified by imaging MRI or contras CT; b. clinical suspicion of malignant lesions requiring pathological confirmation; c. need for immunophenotype clarification for further treatment; d. lesions poorly visualized or inaccessible via conventional biopsy(US or non-contrast CT).Exclusion criteria: a. Incomplete clinical information; b. percutaneous biopsy contraindications (international normalized ratio >1.5, platelet count <50,000/μL [7]); c. no safe puncture route. Inclusion criteria: a. HSOLs identified by imaging MRI or contras CT; b. clinical suspicion of malignant lesions requiring pathological confirmation; c. need for immunophenotype clarification for further treatment; d. lesions poorly visualized or inaccessible via conventional biopsy(US or non-contrast CT). Inclusion criteria: a. HSOLs identified by imaging MRI or contras CT; b. clinical suspicion of malignant lesions requiring pathological confirmation; c. need for immunophenotype clarification for further treatment; d. lesions poorly visualized or inaccessible via conventional biopsy(US or non-contrast CT). Exclusion criteria: a. Incomplete clinical information; b. percutaneous biopsy contraindications (international normalized ratio >1.5, platelet count <50,000/μL [7]); c. no safe puncture route. Exclusion criteria: a. Incomplete clinical information; b. percutaneous biopsy contraindications (international normalized ratio >1.5, platelet count <50,000/μL [7]); c. no safe puncture route. Fig. 1Flow diagram of the patient selection criteria Flow diagram of the patient selection criteria Equipment and materials Guidance device: DSA system (Allura Xper FD20, PHILIPS, Netherlands) with cone-beam CT (CBCT) function.Puncture system: 17G×11cm coaxial positioning needle, 18G×16cm disposable automatic biopsy gun (GALLINI S.R.L, Italy).Catheters: 5F vascular sheath, 5F angiography catheter (TERUMO, Japan), 2.7F microcatheter (TERUMO, Japan).Contrast medium: Iohexol (OMNIPAQUE, 350 mgI/mL, GE, USA).Iodized oil: Super liquid iodized oil (HENGRUI, China; equivalent to iodized oil in composition and clinical efficacy).Embolic agents: Gelatin sponge particles (350–560 μm, Alicon Pharm, China). Guidance device: DSA system (Allura Xper FD20, PHILIPS, Netherlands) with cone-beam CT (CBCT) function. Guidance device: DSA system (Allura Xper FD20, PHILIPS, Netherlands) with cone-beam CT (CBCT) function. Puncture system: 17G×11cm coaxial positioning needle, 18G×16cm disposable automatic biopsy gun (GALLINI S.R.L, Italy). Puncture system: 17G×11cm coaxial positioning needle, 18G×16cm disposable automatic biopsy gun (GALLINI S.R.L, Italy). Catheters: 5F vascular sheath, 5F angiography catheter (TERUMO, Japan), 2.7F microcatheter (TERUMO, Japan). Catheters: 5F vascular sheath, 5F angiography catheter (TERUMO, Japan), 2.7F microcatheter (TERUMO, Japan). Contrast medium: Iohexol (OMNIPAQUE, 350 mgI/mL, GE, USA). Contrast medium: Iohexol (OMNIPAQUE, 350 mgI/mL, GE, USA). Iodized oil: Super liquid iodized oil (HENGRUI, China; equivalent to iodized oil in composition and clinical efficacy). Iodized oil: Super liquid iodized oil (HENGRUI, China; equivalent to iodized oil in composition and clinical efficacy). Embolic agents: Gelatin sponge particles (350–560 μm, Alicon Pharm, China). Embolic agents: Gelatin sponge particles (350–560 μm, Alicon Pharm, China). Technique Preoperative evaluations included electrocardiogram, blood routine, liver/kidney function, coagulation function, tumor markers, chest X-ray, and triphasic enhanced CT/MRI. Hepatic arterial catheterization Patients lay supine on the DSA table with electrocardiogram monitoring. After disinfection and draping, preoperative CBCT was performed. The femoral/radial artery was punctured using the Seldinger technique, and a vascular sheath was inserted. An angiography catheter was advanced to the celiac trunk, superior mesenteric artery, and proper hepatic artery for angiography. If abnormal staining was detected, a microcatheter was superselectively placed into the lesion’s feeding artery, and a mixture of chemotherapy drugs and iodized oil was injected until blood flow ceased, followed by gelatin sponge particles for complete embolization. If no abnormal staining was found, 3.2 ± 1.1 mL of iodized oil was injected into the left/right hepatic artery trunk based on preoperative imaging. The angiography catheter was retained for potential hemostasis. Iodized oil marking and biopsy Post-embolization CBCT confirmed iodized oil deposition (defined as successful marking: visible iodized oil accumulation covering ≥ 50% of the lesion). A 17G coaxial needle was inserted along a preplanned route under fluoroscopy/CBCT guidance. An 18G biopsy gun was used for multi-point sampling (mean: 2.8 samples per patient). After sampling, gelatin sponge strips occluded the puncture tract. Final hepatic arteriography and CBCT excluded bleeding, pleural/peritoneal effusion, or pneumothorax. The catheter was removed, and pressure hemostasis was applied. Specimens were fixed and sent for pathological examination. Figure 2 presents the imaging data of a male patient undergoing Iodized oil marking guided biopsy of liver occupying lesions under the protection of hepatic artery catheterization, including MR examination, DSA fluoroscopy, cone-beam CT and pathological image. Fig. 2The imaging data of a male patient undergoing Iodized oil marking guided biopsy of liver occupying lesions under the protection of hepatic artery catheterization. Figure A: The MR examination findings of the patient. Figure B: The fluoroscopic image after marking the lesion with iodized oil. Figure C: Puncture of the lesion under fluoroscopy. Figure D and E: The CBCT scan verified the puncture site. Figure F: pathological image. The arrow indicates the location of the lesion The imaging data of a male patient undergoing Iodized oil marking guided biopsy of liver occupying lesions under the protection of hepatic artery catheterization. Figure A: The MR examination findings of the patient. Figure B: The fluoroscopic image after marking the lesion with iodized oil. Figure C: Puncture of the lesion under fluoroscopy. Figure D and E: The CBCT scan verified the puncture site. Figure F: pathological image. The arrow indicates the location of the lesion Efficacy and safety evaluation Efficacy Successful sampling (specimens sufficient for pathological diagnosis); positive diagnosis (neoplastic lesions); negative diagnosis (fibrous connective tissue, necrosis, inflammation, or normal cells); diagnostic accuracy (true positives + true negatives)/total cases ×100%. Safety Complications classified by the Clavien–Dindo system [8], including abdominal pain, pneumothorax, pleural and peritoneal effusion, bile duct and vascular injury, intestinal perforation, etc. Abdominal pain was graded using the Numerical Rating Scale (NRS: 0–10), with biopsy-related pain defined as onset within 2 h post-biopsy and resolving within 24 h. Statistical analysis This study mainly adopted descriptive statistical methods. Quantitative data were presented as mean (range) to indicate data distribution, while qualitative data were expressed as frequency (percentage). Fisher’s exact test compared positivity rates between lesion size subgroups. Statistical analysis was conducted using SPSS software (version 26.0, Chicago, IL, USA). Results Patient demographic characteristics and procedure details The demographic characteristics and surgical details of the patients in this study are presented in Table 1. Thirty-nine patients (34 males [87.2%], 5 females [12.8%]; mean age: 56.7 ± 9.8 years) were enrolled. Lesion locations: right anterior lobe (17, 43.6%), right posterior lobe (13, 33.3%), left medial lobe (6, 15.4%), left lateral lobe (2, 5.1%), caudate lobe (1, 2.6%). Table 1Patient demographic characteristics and procedure detailsCharacteristicMean or count(range or percentage)Age(y)56.7 ± 9.8(30–75)Gender Male34(87.2%) Female5(12.8%)Focal diameter <30 mm13(33.3%) >30 mm26(66.7%)Target lesion site Left lateral lobe2(5.1%) Left medial lobe6(15.4%) Right anterior lobe17(43.6%) Right posterior lobe13(33.3%) Caudate lobe1(2.6%)Number of needle insertions1.3 ± 0.4(1–2)Depth of insertion(cm)6.6 ± 1.5(3–9)Number of samples taken2.8 ± 1.1(1–7)Length of tissue(cm)1.2 ± 0.3(0.5–1.5)Procedure time(min)55.6 ± 10.3(41–73) Table 1Patient demographic characteristics and procedure detailsCharacteristicMean or count(range or percentage)Age(y)56.7 ± 9.8(30–75)Gender Male34(87.2%) Female5(12.8%)Focal diameter <30 mm13(33.3%) >30 mm26(66.7%)Target lesion site Left lateral lobe2(5.1%) Left medial lobe6(15.4%) Right anterior lobe17(43.6%) Right posterior lobe13(33.3%) Caudate lobe1(2.6%)Number of needle insertions1.3 ± 0.4(1–2)Depth of insertion(cm)6.6 ± 1.5(3–9)Number of samples taken2.8 ± 1.1(1–7)Length of tissue(cm)1.2 ± 0.3(0.5–1.5)Procedure time(min)55.6 ± 10.3(41–73) Patient demographic characteristics and procedure details Among the 39 lesions, 13 (33.3%) were < 30 mm (pathological positivity rate: 84.6%, 11/13) and 26 (66.7%) were > 30 mm (positivity rate: 92.3%, 24/26). Fisher’s exact test showed no significant difference in biopsy positivity rates between the two groups using 30 mm as the cutoff (P = 1.0). Preoperative imaging: enhanced CT (24, 61.5%), MRI (15, 38.5%). Mean procedure time: 55.6 ± 10.3 min; mean needle insertions: 1.3 ± 0.4; mean insertion depth: 6.6 ± 1.5 cm; mean sample length: 1.2 ± 0.3 cm. Fisher’s exact test verified that there was no significant association between the preoperative imaging modality and the success of biopsy (p = 0.65). Efficacy evaluation All samples yielded pathological results, as shown in Table 2. Among 39 biopsy samples, 35 had positive pathological results (positive rate 89.7%, true positive rate 100%), and 4 had negative results. After follow - up, 3 patients were truly negative and 1 was false negative (false negative rate 25%). The overall accuracy rate of biopsies was 97.4%. The patient with a false - negative result was previously clinically diagnosed with hepatocellular carcinoma, and the biopsy aimed to guide targeted therapy. Multiple TACE treatments had been done, and old iodized oil deposition was thought to affect puncture target judgment. One patient was diagnosed with atypical dysplastic nodules. Preoperative imaging didn’t rule out malignant lesions. After getting pathological results, we and clinical physicians agreed to diagnose the patient with precancerous lesions. After aggressive treatment and follow - up, the patient had a favorable prognosis. Table 2Histopathologic diagnoses from cases of Iodized oil marking liver mass biopsyPathological diagnosisCount(percentage of total)Hepatocellular carcinoma20(51.2%)Cholangiocarcinoma4(10.2%)Adenocarcinoma7(17.9%)Neuroendocrine carcinoma1(2.6%)Melanoma1(2.6%)Bowel cancer1(2.6%)Focal nodular hyperplasia1(2.6%)Chronic inflammatory changes3(7.7%)Nodules of atypical hyperplasia1(2.6%) Table 2Histopathologic diagnoses from cases of Iodized oil marking liver mass biopsyPathological diagnosisCount(percentage of total)Hepatocellular carcinoma20(51.2%)Cholangiocarcinoma4(10.2%)Adenocarcinoma7(17.9%)Neuroendocrine carcinoma1(2.6%)Melanoma1(2.6%)Bowel cancer1(2.6%)Focal nodular hyperplasia1(2.6%)Chronic inflammatory changes3(7.7%)Nodules of atypical hyperplasia1(2.6%) Histopathologic diagnoses from cases of Iodized oil marking liver mass biopsy Safety evaluation Complications (Clavien–Dindo Grade I: 13 cases [33.3%], Grade II: 1 case [2.6%]):Abdominal pain (10 cases, NRS 2–4): 6 biopsy-related, 4 TACE-related.Subcapsular microbleeding (3 cases): resolved spontaneously.Hepatic arterial bleeding (1 case): successfully embolized via the indwelling catheter (Fig. 3) Complications (Clavien–Dindo Grade I: 13 cases [33.3%], Grade II: 1 case [2.6%]):Abdominal pain (10 cases, NRS 2–4): 6 biopsy-related, 4 TACE-related.Subcapsular microbleeding (3 cases): resolved spontaneously.Hepatic arterial bleeding (1 case): successfully embolized via the indwelling catheter (Fig. 3) Complications (Clavien–Dindo Grade I: 13 cases [33.3%], Grade II: 1 case [2.6%]):Abdominal pain (10 cases, NRS 2–4): 6 biopsy-related, 4 TACE-related.Subcapsular microbleeding (3 cases): resolved spontaneously.Hepatic arterial bleeding (1 case): successfully embolized via the indwelling catheter (Fig. 3) Abdominal pain (10 cases, NRS 2–4): 6 biopsy-related, 4 TACE-related. Abdominal pain (10 cases, NRS 2–4): 6 biopsy-related, 4 TACE-related. Subcapsular microbleeding (3 cases): resolved spontaneously. Subcapsular microbleeding (3 cases): resolved spontaneously. Hepatic arterial bleeding (1 case): successfully embolized via the indwelling catheter (Fig. 3) Hepatic arterial bleeding (1 case): successfully embolized via the indwelling catheter (Fig. 3) No Grade III–V complications occurred. Fig. 3A case of a male patient with hepatic artery hemorrhage caused by puncture and its rescue. Figure A: Hepatic arteriography revealed local extravasation of contrast agent. Figure B: The extravasation of contrast agent disappeared after transcatheter arterial chemoembolization A case of a male patient with hepatic artery hemorrhage caused by puncture and its rescue. Figure A: Hepatic arteriography revealed local extravasation of contrast agent. Figure B: The extravasation of contrast agent disappeared after transcatheter arterial chemoembolization The details of adverse events in all cases of liver mass biopsy labeled with lipiodol are presented in Table 3. Table 3Adverse events from cases of iodized oil marking liver mass biopsyAdverse EventsCount(percentage of total)Nothing(grade 0)25(69.4%)Mild (grade I) Abdominal pain10(25.6%) Subcapsular microbleeds3(7.7%)Moderate (grade II) Hemorrhage1(2.6%) Table 3Adverse events from cases of iodized oil marking liver mass biopsyAdverse EventsCount(percentage of total)Nothing(grade 0)25(69.4%)Mild (grade I) Abdominal pain10(25.6%) Subcapsular microbleeds3(7.7%)Moderate (grade II) Hemorrhage1(2.6%) Adverse events from cases of iodized oil marking liver mass biopsy Discussion HSOLs stem from focal pathological changes due to abnormal hepatocyte proliferation or metabolic disturbances. They are common clinically and need careful differential diagnosis [9]. They can be classified as benign or malignant based on their nature. Both are usually asymptomatic in early stages, but malignant lesions progress fast and are often diagnosed late, potentially missing curative treatment. Thus, accurate biopsy of HSOLs is vital for clinical decision-making. Ultrasound-guided percutaneous biopsy is the most commonly used technique, with high success and low complication rates [10]. But its diagnostic yield drops significantly for nodules smaller than 3 cm, with failure rates up to 15% [2, 11], raising the false-negative risk. Although Sonazoid enhanced or fusion ultrasound improves the rate of positive biopsy of small lesions [12, 13], methods to reduce biopsy-related complications, especially bleeding, are limited and highly dependent on operator experience [3, 14]. CT-guided liver biopsy is also widely used. However, some hepatic lesions are isoattenuating on non-contrast CT, making target localization difficult, especially for nodular lesions, thus reducing biopsy success. While contrast-enhanced CT guidance improves visualization, it has limitations like short vascular enhancement duration, difficulty identifying small lesions, and susceptibility to respiratory motion artifacts. Moreover, similar to ultrasound guidance, it lacks real-time monitoring during the procedure, limiting complication management [4]. In hepatic lesions, the lack of lymphocytes, macrophages, and normal vascular structures facilitates iodized oil deposition within the lesion [6]. Iodized oil has been extensively validated in HCC, especially in hypervascular tumors, due to its selective deposition [15]. Although not all lesions show significant iodized oil uptake, characteristic ring-like deposition around the lesion or in abnormal hepatic parenchyma is frequently observed, providing a reliable marker for biopsy targeting. In this study, several cases of cholangiocarcinoma, metastases, and atypical hyperplastic nodules displayed ring-like iodized oil deposition. Some studies reported necrotic tissue in biopsy specimens after iodized oil marking, which may be interpreted as sampling failure, as it can be challenging to distinguish necrotic origins pathologically. iodized oil’s metabolic half-life in tissue is approximately 29–55 days [16], and tumor necrosis typically occurs within 1–2 months [17], which may hinder pathological analysis if biopsy is delayed. In this study, iodized oil did not adversely affect tissue sampling or histopathology [18]. Given that iodized oil’s particle size is 6–7 times that of capillaries, it remains trapped within the capillary network, and short-term hypoxia caused by embolization does not alter cellular structure, thus preserving pathological integrity. Our center’s experience confirms that all specimens were accepted by the pathology department, with no diagnostic difficulties attributed to iodized oil. In our study, the pathological positivity rate of biopsy samples was 89.7%, with a diagnostic accuracy of 97.4%. Gerhards A et al. reported a diagnostic accuracy of 79.3% in CT-guided biopsies after iodized oil marking of confirmed or highly suspected HCC lesions—significantly higher than non-contrast CT (73.8%) and contrast-enhanced CT guidance (65.2%)—although lower than in our study, still highly consistent with our findings [18, 19]. Their study included delays of up to 2 months before biopsy in some cases, potentially contributing to inadequate or necrotic specimens. In our study, biopsy was performed concurrently with TACE, ensuring cellular viability and reducing hospital stay. It should be acknowledged that in a study by Hoffmann P et al. [20], which included more than 300 samples, the accuracy rate of CT-guided biopsy of liver occupying lesions was as high as 95%. The accuracy advantage of our study was not obvious, but our study significantly reduced the number of repeated biopsies. The data from Hoffmann P et al. showed an average of 2.23 punctures per patient for CT-guided liver biopsy, whereas in our study, the average was only 1.31 punctures, with 69.2% of patients achieving success on the first attempt and 30.8% on the second. This advantage is attributed to the combination of fluoroscopy and CBCT real-time guidance, compensating for conventional CT’s inability to monitor biopsy in real time, improving accuracy, minimizing respiratory artifacts, and reducing needle adjustments. Lesion size significantly influences biopsy success, with smaller lesions posing greater technical challenges [21]. Definitions of “small lesions” vary (20–50 mm), complicating direct comparisons. In our study, 13 lesions measured less than 30 mm, with a biopsy positivity rate of 84.6%, which was not significantly different from that of larger lesions. This is attributed to the excellent traceability provided by iodized oil. The most common complication after liver biopsy is abdominal pain, occurring in about 30% of cases, typically mild and self-limited. Persistent or worsening pain may suggest more serious complications such as pneumothorax, biliary or vascular injury, or bowel perforation. Hemorrhage is the most serious complication, with hepatic arterial bleeding being a particular concern [10]. Wei C et al. reported a 5.2% post-biopsy hemorrhage rate among 502 patients with hepatic lesions, with univariate analysis identifying cirrhosis, biopsy volume, and needle depth as risk factors [22]. In our study, the overall bleeding rate was 4.2%, primarily minor subcapsular hemorrhage, managed conservatively. In rare cases of hepatic arterial bleeding, angiography revealed contrast extravasation from the puncture tract, which was successfully treated with super-selective embolization. No severe bleeding or related complications occurred. Thus, biopsy under hepatic arterial catheter protection significantly reduces post-procedural bleeding risk and offers clear clinical advantages. Furthermore, from a cost-benefit perspective, it can be reasonably inferred that for the majority of patients, concurrent biopsy during TACE treatment saves the waiting time for pathological results, and the shortened hospital stay reduces medical costs. Secondly, the 97.4% accuracy rate reduces the rate of repeated biopsies and avoids the necessity of expensive treatment for major bleeding. Of course, in clinical practice, the selection of biopsy methods still needs to comprehensively consider factors such as technical difficulty, potential risks, economic burden and patient willingness. The technology proposed in this study provides a new and feasible solution for clinical decision-making. Conclusions This study confirms that iodized oil marking combined with hepatic arterial catheterization is an efficacious and secure adjunct for percutaneous biopsy of hepatic space-occupying lesions (HSOLs). Its core merits include: (a) improved lesion conspicuity via iodized oil as a radiopaque tracer, synergized with real-time fluoroscopy and CBCT guidance, which enhances biopsy precision and specimen adequacy; (b) concomitant embolotherapeutic and diagnostic efficacy—iodized oil’s embolic property achieves partial tumor control while enabling histopathological confirmation, facilitating subsequent targeted/immunotherapeutic regimens without repeat biopsies, thus optimizing patient compliance and clinical efficiency; (c) mitigated periprocedural bleeding risk through real-time hemorrhage surveillance and puncture tract vascular occlusion via the indwelling hepatic arterial catheter, reducing delayed hemorrhage incidence. In summary, this technique enhances liver biopsy success rate and safety profile, is particularly indicated for high-risk, poorly delineated, or small HSOLs, addresses an unmet technical need in challenging cases, and possesses considerable clinical translational potential.